Related Experiment Video

Updated: Feb 14, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

429

MicroRNA-30a suppresses non-small-cell lung cancer by targeting Myb-related protein B

Guo-Jun Geng1, Ying-Tao Yang2,3, Jie Jiang1

  • 1Department of Thoracic Surgery, The First Hospital Affiliated to Xiamen University, Xiamen, Fujian 361003, P.R. China.

Experimental and Therapeutic Medicine
|February 14, 2018
PubMed

Insights

MicroRNA-30a (miR-30a) is downregulated in non-small-cell lung cancer (NSCLC). Restoring miR-30a levels suppresses tumor growth by targeting Myb-related protein B (MYBL2), suggesting a therapeutic role for miR-30a in NSCLC.

Area of Science:

  • Molecular Biology
  • Oncology

Background:

  • Non-small-cell lung cancer (NSCLC) is a major global cause of cancer mortality.
  • MicroRNAs (miRNAs) play critical roles in cancer cell proliferation, apoptosis, and metastasis.
  • Understanding miRNA regulation is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To investigate the molecular mechanism of miR-30a regulation in NSCLC.
  • To identify and validate Myb-related protein B (MYBL2) as a direct target of miR-30a.
  • To evaluate the functional impact of miR-30a/MYBL2 interaction on NSCLC progression.

Main Methods:

  • Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to assess miR-30a expression.
  • Bioinformatic analysis and dual-luciferase reporter assay to confirm miR-30a targeting of MYBL2.
  • Cell proliferation assays (MTT, BrdU incorporation) and cell cycle analysis to evaluate miR-30a function.
  • In vivo tumor growth assessment.

Main Results:

  • miR-30a was significantly downregulated in NSCLC tissues compared to normal tissues.
  • A negative correlation between miR-30a and MYBL2 expression was observed in NSCLC.
  • Overexpression of miR-30a inhibited NSCLC cell proliferation, induced apoptosis, and caused cell cycle arrest.
  • miR-30a overexpression attenuated tumor growth and reduced MYBL2 expression in vivo.

Conclusions:

  • miR-30a acts as a tumor suppressor in NSCLC by directly targeting and downregulating MYBL2.
  • Restoration of miR-30a levels may represent a potential therapeutic strategy for NSCLC.
  • The miR-30a/MYBL2 axis is a key regulatory pathway in NSCLC pathogenesis.
Keywords:
Myb-related protein BcancermiR-30amiRNAnon-small-cell lung cancer

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.7K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.2K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.5K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K